LUND, Sweden, Oct. 29, 2021 /PRNewswire/ -- Immunovia will
publish the company's interim report for the period January 1 - September 30, 2021 on Thursday, November 11, 2021 at 16:00 CET. Investors, analysts and media are
invited to a telephone conference with web presentation on the same
day at 16:30 CET.
CEO Patrik Dahlen will present
Immunovia and comment on the interim report followed by a Q&A
session. The webcasted telephone conference will be held in
English.
To participate in the telephone conference, please
call:
Sweden: +46 8 505 583
52
United Kingdom:
+44 333 300 92 73
United States:
+1 646 722 49 57
Belgium: +32 262 005
47
Denmark: +45 787 232
51
France: +33 170 750
719
Germany:
+49 692 222 391 65
Norway: +47 239 636
88
Switzerland: +41 225 805
976
Netherlands:
+31 207 219 496
Link to the
webcast: https://financialhearings.com/event/14002
Following the telephone conference, a recording will be
available on Immunovia's website (www.immunovia.com).
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
PanDIA-1.
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
2021.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-interim-report-january---september-2021,c3443310
The following files are available for download:
https://mb.cision.com/Main/13121/3443310/1488591.pdf
|
Press release
(PDF)
|